Testing MT-304 for advanced HER2-positive tumors
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug, MT-304, for people with advanced cancers that have high levels of a protein called HER2. It aims to see if the drug is safe and helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have advanced cancer that has spread and tests positive for HER2 protein.
- Your tumor can be measured on a scan.
- You are able to do your daily activities with little or no help (ECOG 0 or 1).
- Your vital organs (like liver, kidneys, bone marrow) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a new drug (MT-302) in adults with advanced or metastatic epithelial cancers that have worsened or stopped responding to standard treatment. The goal is to see how the drug works and whether it is safe for people with limited options.
This trial tests an experimental oral drug called MTX-531 in people with certain advanced cancers that have not responded to standard treatments. The study aims to see if the drug shrinks tumors or slows their growth, and to find the best dose.
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
This trial tests an investigational drug for people with advanced or metastatic HER2-positive solid tumors. The drug is designed to target cancer cells with HER2 and may slow tumor growth.
This study tests an experimental drug called MTI-301 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth, and to check its safety.
This study tests a new drug (BM230) combined with a PD-1 inhibitor (a type of immunotherapy) for advanced cancers that have HER2. It aims to see if the combination is safe and effective in treating tumors that have stopped responding to standard treatments.
Hear when a new HER2-Expressing Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.